Development and Validation of an AI ‐Assisted Predictive Model Integrating R2 * Mapping and Clinical Indicators for Clinically Significant Prostate Cancer

Documenti analoghi

• PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape
  di: Yanru Chen, et al.
  Pubblicazione: (2025)
• Development and Validation of an MRI‐Based Radiomics Nomogram to Predict the Prognosis of De Novo Oligometastatic Prostate Cancer Patients
  di: Wen‐Qi Liu, et al.
  Pubblicazione: (2024)
• Predicting Pancreatic Cancer in New‐Onset Diabetes Cohort Using a Novel Model With Integrated Clinical and Genetic Indicators: A Large‐Scale Prospective Cohort Study
  di: Yongji Sun, et al.
  Pubblicazione: (2024)
• Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications
  di: Douglas I. Lin, et al.
  Pubblicazione: (2026)
• Establishment of a Novel Risk Stratification System Integrating Clinical and Pathological Parameters for Prognostication and Clinical Decision‐Making in Early‐Stage Cervical Cancer
  di: Haiying Wu, et al.
  Pubblicazione: (2024)